XXXX with leukemic presentation: 10-colour flow cytometry diagnosis and HyperCVAD therapy.

@entity1 @entity404 @entity2940 @entity4210 @entity1195 @entity3052 @entity8282 @entity1544 @entity1778 @entity3053 @entity1116
UNASSIGNED: Few studies describe the comprehensive immunophenotypic pattern of Blastic Plasmacytoid @entity1544 (BPDCN) in the bone marrow and its treatment. This retrospective analysis evaluates the diagnostic flow cytometry pattern and outcome of 9 @entity1 diagnosed with BPDCN. A four tube 10-color flow cytometry (FCM) panel used for diagnosis of @entity3052 , showed cells in the blast gate ( @entity1195 dim/low SSC) and were positive for @entity404 (bright), @entity1116 (dim), @entity2940 (heterogenous), CD123(bright), @entity4210 , @entity3053 , HLA-DR, @entity8282 . Seven @entity1 received front-line induction therapy with HyperCVAD with an overall response rate of 86%. Five of 6 responders underwent planned allogeneic hematopoietic cell transplantation (allo-HCT). For a median follow up of 13.3 months, the 1 year Disease free survival (DFS) and overall survival (OS) were 56% and 67%, respectively. An accurate diagnosis of BPDCN can be made by 10-colour FCM using a 4-tube acute @entity1778 panel demonstrating a characteristic pattern of antigen expression. Front-line induction chemotherapy with HyperCVAD can yield high remission rates, but allo-HCT is required for long term durable remissions. This article is protected by copyright. All rights reserved.
